Gotić M, Rolović Z, Elezović I, Marisavljević D, Berger D
Srp Arh Celok Lek. 1992 Nov;120 Suppl 5:30-2.
Comparison of long term follow-up studies showed that irrespectively of the route of acquisition of HIV infection, the time of progression to AIDS was similar and after 10 years, about 50 per cent of HIV infected individuals had developed AIDS. On the other side, it has been shown that zidovudine improves survival in advanced HIV disease, and that successful results initiated clinical studies with early intervention to determine whether zidovudine could delay the onset of AIDS and prolong the symptom-free clinical stage. The paper reviews results from two main studies, ACTG 019 and ACTG 016, showing that zidovudine treatment reduced disease progression when started in early stages of HIV infection, before development of AIDS. These results influenced the FDA to approve zidovudine for use in HIV infected individuals, both symptomatic and asymptomatic, whose CD4 cell counts are below 500/mm3.
长期随访研究的比较表明，无论感染艾滋病毒的途径如何，发展为艾滋病的时间相似，10年后，约50%的艾滋病毒感染者发展为艾滋病。另一方面，已表明齐多夫定可改善晚期艾滋病毒疾病患者的生存率，并且这些成功结果促使开展早期干预的临床研究，以确定齐多夫定是否能延迟艾滋病的发病并延长无症状临床阶段。本文回顾了两项主要研究ACTG 019和ACTG 016的结果，表明在艾滋病毒感染早期、艾滋病发展之前开始使用齐多夫定治疗可减少疾病进展。这些结果促使美国食品药品监督管理局批准齐多夫定用于CD4细胞计数低于500/mm³的有症状和无症状艾滋病毒感染者。
